{"id":"streptococcus-pneumoniae","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL6068493","moleculeType":"Vaccine component"},"_dailymed":{"setId":"560f84f6-2544-4ba8-8236-a95906eb7d97","title":"SINUS DEFENSE 2.0 (LAC VACCINUM, SILICEA, ASPERGILLUS NIGER, BABESIA MICROTI, BORRELIA BURGDORFERI, CANDIDA ALBICANS, CANDIDA PARAPSILOSIS, CHLAMYDIA TRACHOMATIS, COLIBACILLINUM CUM NATRUM MURIATICUM, CYTOMEGALOVIRUS NOSODE, EHRLICHIA NOSODE, HERPES SIMPLEX I AND II NOSODE, HUMAN PAPILLOMA NOSODE, KLEBSIELLA PNEUMONIAE, MUCOR RACEMOSUS, MYCOBACTERIUM PARATUBERCULOSIS, PNEUMOCCOCCINUM, STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS VIRIDANS, EPSTEIN-BARR VIRUS NOSODE, HERPES ZOSTER NOSODE) SPRAY [MICRO BALANCE HEALTH PRODUCTS LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Streptococcus pneumoniae is a naturally occurring pathogenic bacterium, not a manufactured therapeutic agent. It is the causative agent of pneumococcal diseases including pneumonia, meningitis, and bacteremia. The listing appears to be a data entry error, as bacterial pathogens are not drugs and are not developed by cancer centers as therapeutics.","oneSentence":"This is a bacterial pathogen, not a pharmaceutical drug—Streptococcus pneumoniae is a gram-positive bacterium that causes respiratory and invasive infections.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T05:31:49.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01485029","phase":"NA","title":"Streptococcus Pneumoniae Nasopharyngeal Carriage","status":"COMPLETED","sponsor":"Department of Clinical Research and Innovation","startDate":"2012-01-01","conditions":"Nursery","enrollment":500},{"nctId":"NCT07251465","phase":"","title":"A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2026-01-21","conditions":"Pneumonia","enrollment":846279},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT07488520","phase":"PHASE4","title":"Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire","status":"NOT_YET_RECRUITING","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2026-04","conditions":"Sickle Cell Disease (SCD)","enrollment":120},{"nctId":"NCT07300267","phase":"PHASE1","title":"A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-13","conditions":"Pneumococcal Infection","enrollment":210},{"nctId":"NCT06870409","phase":"PHASE3","title":"Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis","status":"RECRUITING","sponsor":"University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)","startDate":"2025-02-05","conditions":"Endocarditis, Bacterial","enrollment":30},{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT04807660","phase":"","title":"Bacteriological Evaluation of Children With Otorrhea","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2015-10-01","conditions":"Otorrhea","enrollment":1500},{"nctId":"NCT05374018","phase":"","title":"Urinary Antigen Test for Stretococcus Pneumoniae Serotype Prevalence in Community Acquired Pneumonia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2021-12-01","conditions":"Pneumonia","enrollment":1800},{"nctId":"NCT07322549","phase":"","title":"Amoxicillin/Clavulanic Acid Susceptibility in Acute Community-acquired Pneumonia Requiring Intensive Care Management","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2025-03-01","conditions":"Severe Community-acquired Pneumonia","enrollment":104},{"nctId":"NCT07425392","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-02-09","conditions":"Pneumococcal Vaccines","enrollment":720},{"nctId":"NCT06077656","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Inventprise Inc.","startDate":"2023-10-25","conditions":"Pneumococcal Vaccines","enrollment":220},{"nctId":"NCT07284654","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2025-12-01","conditions":"Pneumococcal Vaccines","enrollment":4000},{"nctId":"NCT07216430","phase":"PHASE2","title":"Safety and Efficacy of wSp Vaccine in Young Children","status":"RECRUITING","sponsor":"Serum Life Science Europe GmbH","startDate":"2025-09-29","conditions":"Acute Otitis Media (AOM)","enrollment":320},{"nctId":"NCT07135453","phase":"PHASE4","title":"Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03","conditions":"Vaccine, Pneumococcal Disease","enrollment":70},{"nctId":"NCT07023081","phase":"PHASE1","title":"A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-06-15","conditions":"Pneumococcal Disease","enrollment":200},{"nctId":"NCT06622109","phase":"","title":"A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-11-25","conditions":"Pneumococcal Disease","enrollment":1100},{"nctId":"NCT06760208","phase":"","title":"A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-13","conditions":"Pneumococcal Immunization, Safety","enrollment":660},{"nctId":"NCT06177912","phase":"PHASE3","title":"A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-18","conditions":"Pneumococcal Infection","enrollment":882},{"nctId":"NCT06782282","phase":"","title":"A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-01-20","conditions":"Community-Acquired Pneumonia (CAP)","enrollment":22234435},{"nctId":"NCT06531538","phase":"PHASE2","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-07-30","conditions":"Pneumococcal Disease","enrollment":225},{"nctId":"NCT07460154","phase":"NA","title":"Structured Review: To Optimise Management and Prevent Harm in COPD","status":"NOT_YET_RECRUITING","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2026-03-01","conditions":"COPD","enrollment":96},{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT07365826","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-01-12","conditions":"Pneumococcal Vaccines","enrollment":1300},{"nctId":"NCT06049134","phase":"PHASE4","title":"Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-10-06","conditions":"Lymphoma","enrollment":30},{"nctId":"NCT05568654","phase":"NA","title":"Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2022-11-01","conditions":"Community-Acquired Pneumonia, Antimicrobial Stewardship, Point-of-Care Testing","enrollment":12500},{"nctId":"NCT07252791","phase":"PHASE4","title":"Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-16","conditions":"Autoimmune Rheumatologic Disease","enrollment":114},{"nctId":"NCT06128915","phase":"PHASE4","title":"The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses","status":"RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2024-01-08","conditions":"Aging","enrollment":60},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT06975878","phase":"PHASE3","title":"Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-05-22","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":1092},{"nctId":"NCT05569954","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-07","conditions":"Pneumococcal Disease","enrollment":1484},{"nctId":"NCT07017777","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-11-14","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":600},{"nctId":"NCT07019909","phase":"PHASE1","title":"A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-07-06","conditions":"Pneumococcal Disease","enrollment":400},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT07428759","phase":"PHASE1","title":"Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-10","conditions":"Pneumonia, Bacterial","enrollment":120},{"nctId":"NCT02148796","phase":"PHASE2","title":"Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2017-01-01","conditions":"Asthma, Wheezing","enrollment":822},{"nctId":"NCT00339157","phase":"PHASE2, PHASE3","title":"Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2006-05-11","conditions":"Systemic-Onset Juvenile Idiopathic Arthritis","enrollment":24},{"nctId":"NCT06181656","phase":"","title":"Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-02-05","conditions":"Pneumococcal Vaccine, Esophageal Cancer, Lymphopenia","enrollment":80},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT07418372","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2026-03-12","conditions":"Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria","enrollment":660},{"nctId":"NCT05183854","phase":"PHASE2","title":"Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-01-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":60},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT07406334","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-05-15","conditions":"Pneumonia, Bacterial","enrollment":45},{"nctId":"NCT07406347","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-07-10","conditions":"Pneumonia, Bacterial","enrollment":60},{"nctId":"NCT04214444","phase":"PHASE3","title":"Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2020-07-03","conditions":"Pneumococcal Infections, Lymphoma, Large B-Cell, Diffuse","enrollment":26},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT05393037","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Disease","enrollment":313},{"nctId":"NCT04845945","phase":"","title":"MISP 60528 Pneumococcal Vaccination","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2021-06-10","conditions":"Heart Transplant Infection Prevention","enrollment":4},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT04745559","phase":"PHASE2","title":"Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-02-18","conditions":"Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL)","enrollment":26},{"nctId":"NCT06183216","phase":"PHASE1","title":"A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2024-01-04","conditions":"Pneumococcal Infectious Disease","enrollment":140},{"nctId":"NCT07247188","phase":"PHASE3","title":"Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT06550830","phase":"PHASE1","title":"Clinical Trial of PCV24 in Children Aged 2-17 Years","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-09-07","conditions":"Pneumococcal Infectious Disease","enrollment":119},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT06617715","phase":"PHASE3","title":"Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-10-23","conditions":"Pneumococcal Infectious Disease","enrollment":3080},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":"Pneumococcal Infections","enrollment":310},{"nctId":"NCT05452941","phase":"","title":"A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-10-27","conditions":"Pneumonia","enrollment":12500},{"nctId":"NCT05622682","phase":"","title":"Vaccine Immune Recovery After Leukemia","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2022-09-28","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":89},{"nctId":"NCT06720038","phase":"PHASE2","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2024-11-25","conditions":"Pneumococcal Vaccines","enrollment":905},{"nctId":"NCT04193215","phase":"PHASE3","title":"V114 and Acute Otitis Media (V114-032/PNEU-ERA)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-09-12","conditions":"Acute Otitis Media (AOM)","enrollment":7119},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07354425","phase":"","title":"Pneumococcal Community-Acquired Pneumonia Requiring Hospitalization Among Colombian Adults","status":"COMPLETED","sponsor":"Universidad de la Sabana","startDate":"2022-06-28","conditions":"Community Acquired Pneumonia (CAP), Pneumococcal Pneumonia","enrollment":688},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT07333352","phase":"PHASE2","title":"PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months","status":"RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2025-09-11","conditions":"Pneumococcal Infectious Disease","enrollment":480},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT05417165","phase":"PHASE2","title":"Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Seema Bhat","startDate":"2023-09-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":80},{"nctId":"NCT07071909","phase":"PHASE1, PHASE2","title":"Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells","status":"WITHDRAWN","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-01-20","conditions":"Malignancy, Cancer, Hematological Malignancies","enrollment":""},{"nctId":"NCT05815264","phase":"PHASE1","title":"Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2020-09-07","conditions":"Pneumonia","enrollment":144},{"nctId":"NCT06675032","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-27","conditions":"Pneumococcal Infectious Disease","enrollment":230},{"nctId":"NCT07105722","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-12","conditions":"Pneumonia, Bacterial","enrollment":127},{"nctId":"NCT07300644","phase":"PHASE2","title":"Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-11-25","conditions":"Pneumococcal Infectious Disease","enrollment":420},{"nctId":"NCT06822907","phase":"PHASE4","title":"Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-01","conditions":"Acute Febrile Illness, Pneumococcal Infections","enrollment":1052},{"nctId":"NCT06817421","phase":"PHASE4","title":"Opportunistic Pneumococcal Immunisation Trial in MALnutrition","status":"NOT_YET_RECRUITING","sponsor":"Nick Fancourt","startDate":"2026-01","conditions":"Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines","enrollment":214},{"nctId":"NCT06678620","phase":"PHASE2","title":"Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-20","conditions":"Pneumococcal Infectious Disease","enrollment":992},{"nctId":"NCT05512819","phase":"PHASE3","title":"A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-16","conditions":"Pneumococcal Disease","enrollment":541},{"nctId":"NCT06736288","phase":"PHASE4","title":"Post Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs).","status":"RECRUITING","sponsor":"Laboratorio Farmaceutico SIT srl","startDate":"2025-10-21","conditions":"Respiratory Infection, Lower Respiratory Tract Infection (LRTI)","enrollment":240},{"nctId":"NCT07243236","phase":"","title":"Impact of Vaccine Funding by the National Health Insurance on Vaccination Coverage Among Patients Targeted by Current Vaccination Recommendations and Followed in Outpatient Consultations","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-11-19","conditions":"Healthcare Providers, Postpartum","enrollment":2920},{"nctId":"NCT04350502","phase":"NA","title":"Pharmacokinetics and Pleural Fluid Penetration of Amoxicillin and Clavulanic Acid in Patients With Pleural Infections","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2019-07-18","conditions":"Pleural Infection, Empyema, Community-acquired Pneumonia","enrollment":11},{"nctId":"NCT02232191","phase":"PHASE2","title":"Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2014-12","conditions":"Asplenia","enrollment":75},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT05060146","phase":"NA","title":"Prevention of Pneumococcal Infections: Impact Collaborative Medico-pharmaceutical Care Structured to Improve Vaccination Coverage of Patients at Risk.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-09-19","conditions":"Streptococcus Pneumoniae Infection","enrollment":646},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT04734925","phase":"","title":"Study of the Impact of an Intervention Performed by a Clinical Pharmacist on Patients at Risk of Pneumococcal Infection at the End of Hospitalization","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2020-03-01","conditions":"Vaccination","enrollment":167},{"nctId":"NCT01351896","phase":"PHASE2","title":"Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-02","conditions":"Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia","enrollment":49},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT02052154","phase":"PHASE2","title":"Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-03-10","conditions":"Splenectomized Patients","enrollment":70},{"nctId":"NCT04153682","phase":"NA","title":"Trial on a Strategy Combining Rapid Diagnostic Testing and Antimicrobial Stewardship to Improve Antibiotic Use in Patients With Hospital-acquired Pneumonia.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-02-21","conditions":"Hospital-acquired Pneumonia","enrollment":116},{"nctId":"NCT05979350","phase":"NA","title":"Metagenomic NGS for Diagnosis of Pneumonia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2023-08-07","conditions":"Pneumonia, Diagnosis","enrollment":114},{"nctId":"NCT07135427","phase":"PHASE4","title":"Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-09-03","conditions":"Alpha 1-Antitrypsin, COPD, Antibody Deficiency","enrollment":30},{"nctId":"NCT05526716","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-09-23","conditions":"Pneumonia, Pneumococcal","enrollment":1080},{"nctId":"NCT07059182","phase":"PHASE1","title":"Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Serum Life Science Europe GmbH","startDate":"2025-06-11","conditions":"PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media","enrollment":30},{"nctId":"NCT01802086","phase":"NA","title":"Emla-Cream as Pain Relief During Pneumococcal Vaccination","status":"COMPLETED","sponsor":"Beatrice Olsson Duse","startDate":"2013-05","conditions":"Children, Pain","enrollment":72},{"nctId":"NCT05412030","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-06-16","conditions":"Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal","enrollment":388},{"nctId":"NCT05794191","phase":"","title":"A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-22","conditions":"HIV, Pneumonia, Infections, Pneumococcal","enrollment":350399},{"nctId":"NCT06182124","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-12-20","conditions":"Pneumococcal Disease","enrollment":558}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29862,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prevnar","PCV7"],"phase":"marketed","status":"active","brandName":"Streptococcus pneumoniae","genericName":"Streptococcus pneumoniae","companyName":"Ohio State University Comprehensive Cancer Center","companyId":"ohio-state-university-comprehensive-cancer-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}